Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that, on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its meeting held on July 25, 2025, has approved appointment of Mr. Deepak Shukla as Chief Executive - API Business in capacity of a Senior Management Personnel of the Company w.e.f. July 28, 2025.

RPG Life Sciences has appointed Mr. Deepak Shukla as Chief Executive of its API (Active Pharmaceutical Ingredients) Business, classifying him as Senior Management Personnel. The appointment, effective July 28, 2025, was approved by the Board on July 25, 2025, based on the recommendation of the Nomination and Remuneration Committee. Mr. Shukla is an external hire with around 25 years of experience in the pharma and chemicals industry, having worked at UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy's Laboratories. He holds a B.Tech in Chemical Engineering and an Executive MBA in International Business from IIFT, New Delhi. His responsibilities will cover end-to-end operations, business restructuring, API manufacturing, and global supply chain for the API division.